A Phase III Study Comparing Irinotecan and Cisplatin with Etoposide and Cisplatin for Adjuvant Chemotherapy of Completely Resected Pulmonary High-grade Neuroendocrine Carcinoma (JCOG1205/1206, HGNEC-EP/IP-P3) - A Phase III Study Comparing Irinotecan and Cisplatin with Etoposide and Cisplatin for Adjuvant Chemotherapy of Completely Resected Pulmonary High-grade Neuroendocrine Carcinoma (JCOG1205/1206, HGNEC-EP/IP-P3)

Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 220 人开始时间: 2013年3月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Synchronous or metachronous (within 5 years) malignancies except carcinoma in situ or intramucosal tumor curatively treated with local therapy 2) Active infection requiring systemic therapy 3) Body temperature >= 38 degrees Celsius 4) Pregnant or lactating women or women of childbearing potential 5) Psychiatric disease 6) Serious postoperative complications 7) Patients requiring systemic steroids medication 8) Poorly controlled diabetes mellitus or routine administration of insulin 9) Poorly controlled hypertension 10) Unstable angina within 3 weeks, or with a history of myocardial infarction within 6 months 11) Positive HBs antigen 12) Positive HIV antibody 13) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema

发起方

Japan Clinical Oncology Group (JCOG)